07:00 , Aug 19, 2013 |  BC Week In Review  |  Clinical News

ATLP-03 regulatory update

Atlantic said following its pre-IND meeting with FDA that it plans to develop ATLP-03, an immediate-release, abuse-deterrent formulation of pain drug oxycodone, under section 505(b)(2) of the Food, Drug and Cosmetic Act. The section allows...
08:00 , Jan 7, 2013 |  BC Week In Review  |  Company News

Atlantic Pharmaceuticals drug delivery news

On Dec. 20, 2012, the company said the U.S. Patent and Trademark Office issued two patents covering Atlantic's SMART/Script tamper-resistant drug delivery technology. The patents, U.S. Patent Nos. 8,187,636 and 8,349,362, cover dosage forms for...
07:00 , Jul 12, 2010 |  BC Week In Review  |  Company News

Atlantic Healthcare management update

Atlantic Healthcare Ltd. , London, U.K.   Business: Autoimmune   Hired: Huw Jones as CEO of Atlantic's Atlantic Pharmaceuticals Ltd. division, formerly a director at Ardana plc and president for Europe at CV Therapeutics Inc....
08:00 , Mar 27, 2000 |  BC Week In Review  |  Company News

Atlantic Pharmaceuticals Inc. ophthalmic, cardiovascular, gene/cell therapy news

The company changed its name to Atlantic Technology Ventures Inc. , while maintaining its ATLC trading symbol. Atlantic Pharmaceuticals Inc. (ATLC), Raleigh, N.C.   Business: Ophthalmic, Cardiovascular, Gene/Cell therapy  ...
07:00 , Oct 25, 1999 |  BC Week In Review  |  Clinical News

Atlantic Pharmaceuticals Inc. preclinical data

ATLC published in Pharmacology and Experimental Therapeutics that in mice, CT-3 had analgesic effects and potency similar to morphine, but with a longer duration. CT-3 produced no gastrointestinal ulceration when administered with DMSO acutely at...
07:00 , Oct 18, 1999 |  BC Week In Review  |  Company News

Atlantic Pharmaceuticals Inc., University of Pennsylvania deal

ATLC subsidiary Channel Therapeutics Inc. terminated its 1994 license agreement with the university, returning all rights to the university's Beta-cyclodextrin tetradecasulfate (B-CDT) technology to prevent restenosis following angioplasty, which ATLC said no longer fits its...
07:00 , Aug 2, 1999 |  BC Week In Review  |  Company News

Atlantic Pharmaceuticals Inc. other research news

ATLC's Gemini Technologies subsidiary received a $100,000 SBIR grant from an undisclosed NIH agency to fund a preclinical study of 2-5A. Atlantic Pharmaceuticals Inc. (ATLC), Raleigh, N.C.   Product: 2-5A antisense enhancer   Use: Inhibit...
07:00 , Jun 1, 1999 |  BC Week In Review  |  Company News

Atlantic Pharmaceuticals Inc. board of directors update

(Restructuring, see above) Atlantic Pharmaceuticals Inc. (ATLC), Raleigh, N.C.   Business: Autoimmune/Inflammation, Cardiovascular, Ophthalmic   Appointed: Frederick Zoto, a patent attorney and technology licensing consultant; and Joseph Rudick, ophthalmologist at Associate Ophthalmologist P.C. who also...
07:00 , Jun 1, 1999 |  BC Week In Review  |  Company News

Atlantic Pharmaceuticals Inc. autoimmune/inflammation, cardiovascular, ophthalmic news

ATLC said it will reduce headcount to 5 from 8 to preserve working capital and expand development of its cataract surgery technology. (Board, see below) Atlantic Pharmaceuticals Inc. (ATLC), Raleigh, N.C.   Business: Autoimmune/Inflammation, Cardiovascular,...
08:00 , Jan 4, 1999 |  BC Week In Review  |  Company News

Atlantic Pharmaceuticals Inc. board of directors update

Atlantic Pharmaceuticals Inc. (ATLC), Raleigh, N.C.   Business: Autoimmune/Inflammation, Cardiovascular, Ophthalmic   Appointed: Martin Cleary, co-founder of CardioGene Therapeutics Inc. and a pharmaceutical consultant  ...